drugset / Trial / NCT01745458
SB-659032 Platelet Aggregation Study
RandomizedCrossoverDouble-blindTreatment
Summary
This study is designed to assess whether inhibition of plasma Lp-PLA2 activity impacts platelet function as assessed by ex vivo platelet aggregation tests and in vivo plasma biomarkers.
Timeline
- Start
- 2005-07
- Primary completion
- 2005-12
- Completion
- 2005-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Rilapladib | Small molecule | 250 mg | Oral |